Affordable, Effective and Innovative Product Solutions Key Drivers of European Respiratory Diseases Market
Posted on: Tuesday, 3 October 2006, 03:00 CDT
LONDON, October 3 /PRNewswire/ -- The respiratory market in Europe is facing a challenging environment due to the ongoing lack of innovative drugs. Currently, primarily combination drugs drive the market with top brands facing no real competition from generic alternatives. The emergence of affordable, innovative and effective inhalers and product solutions will provide impetus to market growth.
Frost & Sullivan (http://www.pharma.frost.com/) finds that the European Respiratory Diseases Market earned revenues of US$5.84 billion in 2005 and estimates this to reach US$10.43 billion in 2012.
"Combination drugs are the future of European respiratory therapeutics, which will gain significant momentum and impel market growth in Europe," says Frost & Sullivan Research Analyst Sylvia Miriyam Findlay. "At the same time, market expansion will be driven by the uptake of more efficacious drug delivery techniques that promote improved treatment regimes in asthma/COPD patients."
However, the lack of new drugs on the horizon will slow down overall growth rates. The R&D pipelines of major participants regarding respiratory drugs are not very promising and such a scenario will restrain market expansion.
"Though the European market has limited generic competition, it is essential to maximise on revenues generated by top selling drugs before their patents expire," advises Ms. Findlay. "Effective life-cycle management including product line extensions to cover other respiratory illnesses will be the best way to gain competitive advantage."
In addition to effective life cycle management, pharmaceutical companies need to increase their investments in R&D and develop more efficient and cost-effective drugs that support improved disease management.
European Respiratory Diseases Market is part of the Pharmaceutical & Clinical Diagnostics Subscription, which also includes research in the following markets: European Alzheimer's Market, European Diabetes Market and European CNS Market.All research included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants. Interviews with the press are available.
If you are interested in a virtual brochure, which provides manufacturers, end users, and other industry participants with an overview of the latest analysis of the European Respiratory Diseases Market (H043-52) then send an e-mail to Radhika Menon Theodore- rmtheodore@frost.com - Corporate Communications at rmtheodore@frost.com with the following information: your full name, company name, title, telephone number, e-mail address, city, state, and country. We will send you the information via email upon receipt of the above information.
Frost & Sullivan, a global growth consulting company, has been partnering with clients to support the development of innovative strategies for more than 40 years. The company's industry expertise integrates growth consulting, growth partnership services, and corporate management training to identify and develop opportunities. Frost & Sullivan serves an extensive clientele that includes Global 1000 companies, emerging companies, and the investment community by providing comprehensive industry coverage that reflects a unique global perspective and combines ongoing analysis of markets, technologies, econometrics, and demographics. For more information, visit http://www.frost.com/.
Contact: Radhika Menon Theodore Corporate Communications - Europe P: +91-44-42044541 F: +91-44-24314264 E: rmtheodore@frost.com Melina Trevino Corporate Communications - Americas P: +1-210-247-2440 F: +1-210-348-1003 E: melina.trevino@frost.com Surbhi Dedhia Corporate Communications - India P: +91-22-5001-3431 E: sdedhia@frost.com Jasminder Kaur Corporate Communications - Asia Pacific P: +65-68900937 E: jkaur@frost.com Sharmin Jassal Corporate Communications - Australia P: +61-2-8247-8900 F: +61-2-9252-8066 E: sjassal@frost.com http://www.frost.com/
Keywords in this release: Europe, respiratory market, market, respiratory drugs, combination drugs, inhalers, respiratory therapeutics, drug delivery techniques, COPD, asthma, respiratory illnesses
Frost & Sullivan
CONTACT: Contact: Radhika Menon Theodore, Corporate Communications -Europe, P: +91-44-42044541, F: +91-44-24314264, E: rmtheodore@frost.com.Melina Trevino, Corporate Communications - Americas, P: +1-210-247-2440, F:+1-210-348-1003, E: melina.trevino@frost.com. Surbhi Dedhia, CorporateCommunications - India, P: +91-22-5001-3431, E: sdedhia@frost.com. JasminderKaur, Corporate Communications - Asia Pacific, P: +65-68900937, E:jkaur@frost.com. Sharmin Jassal, Corporate Communications - Australia, P:+61-2-8247-8900 F: +61-2-9252-8066, E: sjassal@frost.com
Source: PRNewswire
Related Articles
- Glen's Markets Adds Discounted Generic Drug Program
- Roche Files Marketing Application for Leukaemia Drug in Adults
- European Commission Grants Marketing Authorization for MediGene's Drug Oracea
- Intelliden Receives 2007 Product of the Year Award From Technology Marketing Corporation
- Diabetes Drugs Emerge As Top Force in Drug Spending Growth
- Clinical Data and Affymetrix Announce Marketing Agreement for New Drug Metabolism Service
- SecureLogix Corporation Receives Communications Solutions(TM) Magazine's 'Product of the Year' Award for 2004
- Technology Marketing Corporation and IPCC Sign Memorandum of Understanding
- Toshiba Awarded 2004 Innovation Award By Technology Marketing Corporation's TMC Labs
- Lucent Technologies Software Awarded 2003 'Product of the Year' By Technology Marketing Corporation's Communications Solutions Magazine
 |
 |
User Comments (0)
RSS Feeds